share_log

Vertex Pharmaceuticals | SC TO-C: Written communication relating to an issuer or third party tender offer

Vertex Pharmaceuticals | SC TO-C: Written communication relating to an issuer or third party tender offer

福泰制药 | SC TO-C：投标报价书面通信
SEC announcement ·  04/10 17:24
Moomoo AI 已提取核心信息
Vertex Pharmaceuticals Incorporated has announced its intention to acquire Alpine Immune Sciences, Inc. in an all-cash transaction valued at approximately $4.9 billion, or $65 per share. The acquisition, unanimously approved by the Boards of Directors of both companies, is expected to close in Q2 of 2024, subject to majority tender and customary closing conditions. This strategic move aims to enhance Vertex's capabilities in developing transformative medicines for serious diseases with high unmet need, particularly in specialty markets. Alpine's lead asset, povetacicept, is a Phase 3-ready therapy with potential to treat IgAN, a serious autoimmune kidney disease, and other conditions. The transaction is consistent with Vertex's investment strategy and is fully funded from cash on hand. The Tender Offer Statement and related materials will be filed with the SEC at the commencement of the tender offer, and Alpine's stockholders are urged to read these materials carefully when they become available.
Vertex Pharmaceuticals Incorporated has announced its intention to acquire Alpine Immune Sciences, Inc. in an all-cash transaction valued at approximately $4.9 billion, or $65 per share. The acquisition, unanimously approved by the Boards of Directors of both companies, is expected to close in Q2 of 2024, subject to majority tender and customary closing conditions. This strategic move aims to enhance Vertex's capabilities in developing transformative medicines for serious diseases with high unmet need, particularly in specialty markets. Alpine's lead asset, povetacicept, is a Phase 3-ready therapy with potential to treat IgAN, a serious autoimmune kidney disease, and other conditions. The transaction is consistent with Vertex's investment strategy and is fully funded from cash on hand. The Tender Offer Statement and related materials will be filed with the SEC at the commencement of the tender offer, and Alpine's stockholders are urged to read these materials carefully when they become available.
Vertex Pharmicals Incorporated宣布打算以价值约49亿美元，合每股65美元的全现金交易收购Alpine Immune Sciences, Inc.此次收购获得了两家公司董事会的一致批准，预计将于2024年第二季度完成，但须遵守多数招标和惯例成交条件。这一战略举措旨在增强Vertex开发针对需求量大的严重疾病的变革性药物的能力，尤其是在专业市场。Alpine的主要资产povetacept是一种三期就绪的疗法，有可能治疗IgAn、一种严重的自身免疫性肾脏疾病和其他疾病。该交易符合Vertex的投资策略，资金完全来自手头现金。要约声明和相关材料将在要约开始时向美国证券交易委员会提交，我们敦促阿尔派的股东在这些材料可用后仔细阅读。
Vertex Pharmicals Incorporated宣布打算以价值约49亿美元，合每股65美元的全现金交易收购Alpine Immune Sciences, Inc.此次收购获得了两家公司董事会的一致批准，预计将于2024年第二季度完成，但须遵守多数招标和惯例成交条件。这一战略举措旨在增强Vertex开发针对需求量大的严重疾病的变革性药物的能力，尤其是在专业市场。Alpine的主要资产povetacept是一种三期就绪的疗法，有可能治疗IgAn、一种严重的自身免疫性肾脏疾病和其他疾病。该交易符合Vertex的投资策略，资金完全来自手头现金。要约声明和相关材料将在要约开始时向美国证券交易委员会提交，我们敦促阿尔派的股东在这些材料可用后仔细阅读。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息